Shed Tumor Gangliosides and Progression of Human Neuroblastoma

By Leonard Valentino, Thomas Moss, Erik Olson, He-Jing Wang, Robert Elashoff, and Stephan Ladisch

Shedding of membrane gangliosides is characteristic of human and experimental tumors. Because some shed tumor gangliosides have potent tumor-enhancing properties, significant ganglioside shedding could influence tumor progression. We examined this possibility in a human tumor, neuroblastoma. Ganglioside shedding, measured as circulating tumor-derived ganglioside, and the outcome of 74 patients with advanced stage (III and IV) disease were studied. Progression-free survival (PFS) was inversely related to circulating ganglioside levels at the time of diagnosis (P = .018). By Kaplan-Meier analysis, the quartile of patients having the highest circulating ganglioside levels (≥688 pmol/mL) had a strikingly different outcome from the quartile of patients with the lowest (≤103 pmol/mL) ganglioside levels (P = .013): median PFS was shorter (9 vs 28 months), and the long-term survival rate lower (2-year PFS of 24% vs 70%). We conclude that more rapid disease progression and lower survival rate are associated with high circulating ganglioside levels at diagnosis and speculate that shed neuroblastoma tumor gangliosides play a role in accelerating tumor progression.

© 1990 by The American Society of Hematology.

MATERIALS AND METHODS

Patients. Seventy-four children with histologically confirmed, advanced stage, neuroblastoma, diagnosed between 1979 and 1987, were studied. Thirty-two patients had stage III, 42 had stage IV, and none had stage IVs disease according to the Children’s Cancer Study Group (CCSG) classification.1 The median patient age at the time of diagnosis was 29 months (range, 1 to 128 months). All patients received similar intensive chemotherapy at CCSG member institutions on CCSG protocols, and some also underwent surgical resection, radiation therapy, and/or bone marrow transplantation.

Patient samples. Plasma/serum specimens were obtained at the time of diagnosis, before the institution of therapy, and were stored at −70°C until the time of ganglioside analysis.

Ganglioside purification and quantitation. Gangliosides were purified from plasma or serum by a recently developed micro-method that consists of total lipid extraction of the sample with chloroform/methanol, partition of the total lipid extract in diisopropyl ether/1-butanol/water, and gel filtration.14 The purified total circulating gangliosides were analyzed by high-performance thin-layer chromatography (HPTLC), using HPTLC plates (Merek, Darmstadt, FRG) developed in chloroform-methanol-0.25% aqueous CaCl₂ (60:40:9) and stained with resorcinol. The G₂₀ in patient samples was quantitated by densitometric scanning of the HPTLC band.14

Clinical evaluation. The patient’s medical record was reviewed to determine the initial progression-free period. Physical examination, isotopic bone scans, computerized axial tomography, magnetic resonance imaging, urinary catecholamine quantitation, and bone marrow histopathology were used to monitor patients. The endpoint of the clinical analysis was the documentation of progressive disease (PD), defined as an increase by 25% of established primary disease, the recurrence of marrow disease, or the occurrence of any new lesion.8 Absence of disease progression (NPD) (ie, stable disease, regressing disease, or disease in clinical remission) was confirmed by contact with the primary physician of each patient, most recently in March 1989.

Statistical analysis. The relationship between progression of disease and clinical stage, age at diagnosis, and circulating G₂₀ (log G₂₀) concentration was evaluated by the univariate proportional hazards regression model using the Cox and Oakes test.10 To quantify the relationship between circulating G₂₀ levels at diagnosis and PFS, patients were grouped into quartiles by their G₂₀ levels. The impact of the most disparate G₂₀ levels was determined by comparison of patients in quartiles 1 and 4, analyzed by the chi-square test at the 2-year time-point, and by the method of Kaplan-Meier11 to estimate the PFS distribution for these groups. The log rank statistic12 was used to test equality of PFS curves, and the 95% confidence intervals (CI) were computed using the modified reflected method.12

From the Departments of Pediatrics and Biostatistics, the Gwynne Hazen Cherry Memorial Laboratory and the Johnson Cancer Center, UCLA School of Medicine; and the Children's Cancer Study Group, Los Angeles, CA.

Submitted September 15, 1989; accepted December 8, 1989.

Supported by Grants CA42361, CA02649, and CA13539 from the National Cancer Institute, Grant PDT-270 from the American Cancer Society; and by the Phi Beta Psi Sorority.

This work was presented in part at the American Society of Hematology meeting, December 1988, San Antonio, TX (Blood 72:171a, 1988 [abstr]).

Address reprint requests to Stephan Ladisch, MD, Division of Hematology/Oncology, Department of Pediatrics, UCLA School of Medicine, Los Angeles, CA 90024-1752.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1990 by The American Society of Hematology.

0006-4917/90/7507-01564-017 @ 1990 by The American Society of Hematology.

Blood. Vol 75, No 7 (April 1), 1990: pp 1564-1567


RESULTS

G\textsubscript{D2} ganglioside quantitation. The total plasma ganglioside patterns of three neuroblastoma patients are shown in Fig 1. They show the presence of tumor-derived G\textsubscript{D2}. The median and range of circulating G\textsubscript{D2} concentrations of all 74 patients are summarized in Table 1; the G\textsubscript{D2} content of some samples has been previously reported.\textsuperscript{11} The range of G\textsubscript{D2} concentrations varied from below the limit of chemical detection (<2 pmol/mL) to more than 2 \times 10\textsuperscript{3} pmol G\textsubscript{D2}/mL plasma, or 1,000 times the normal plasma G\textsubscript{D2} concentration of <2 pmol/mL,\textsuperscript{13} and the median circulating G\textsubscript{D2} concentration of stage IV patients was not statistically different from that of stage III patients (Table 1). These results confirm our previous finding of lack of a statistically significant correlation between clinical stage and circulating G\textsubscript{D2} levels,\textsuperscript{6} and suggest that high levels at diagnosis are not merely a reflection of advanced stage. Finally, the G\textsubscript{D2} levels were unrelated to age at diagnosis (r = -0.08, P = .44).

Disease status. Twenty-eight patients remain alive without PD. Two other patients died 3 and 8 months after diagnosis without PD (of complications related to therapy), and three others without PD were lost to follow-up 2, 12, and 99 months after diagnosis. The median follow-up of patients without disease progression is 18 months (range 2 to 101 months). Progressive disease occurred in the other 41 patients (55%): within 6 months of diagnosis in 25 patients, within 7 to 12 months in 7 patients, during the second year in 5 patients, and later in 4 patients. These findings yield an overall 3-year actuarial PFS of 32%, and median PFS of 15 months (CI, 8 to 28 months) for patients with advanced-stage neuroblastoma, consistent with recent survival statistics.\textsuperscript{14}

When patient outcome was analyzed according to stage, 34% of stage III patients had PD (median PFS, >101 months), in contrast to 71% of stage IV patients (median PFS, 8 months). Thus, clinical stage was significantly related to PFS (P < .001), as expected.\textsuperscript{7} A negative prognostic impact of older age at diagnosis\textsuperscript{15} was not confirmed in this study (P > .4), possibly because there were too few infants (n = 13).

Pretreatment circulating G\textsubscript{D2} concentration and progression-free survival. The relationship between pretreatment G\textsubscript{D2} levels and the occurrence of PD within 2 years of diagnosis is shown in Table 2 and Fig 2. All patients who are actually evaluable for disease progression at 2 years (ie, surviving 2 years without PD or having had PD documented within 2 years of diagnosis) were included (n = 52). Of the patients whose circulating G\textsubscript{D2} levels were in the lowest (first) quartile, only 46% had PD, in contrast to 92% of the patients whose circulating G\textsubscript{D2} levels were in the highest (fourth) quartile (P = .01). A continuous increase in the percentage of patients with PD is observed as the G\textsubscript{D2} concentration increases from the lowest to the highest quartile (Fig 2). Thus, the occurrence of PD is directly related to the G\textsubscript{D2} level at diagnosis. This is consistent with the hypothesis that shedding of tumor gangliosides may be an important factor in tumor progression.

A highly significant relationship between the pretreatment circulating G\textsubscript{D2} concentration and PFS was also demonstrated when the log G\textsubscript{D2} concentration was considered as a continuous variable. PFS decreased with increasing G\textsubscript{D2} level at diagnosis (P = .018). When patients were grouped into quartiles and those with the most disparate G\textsubscript{D2} levels compared by life-table analysis (quartiles 1 v 4, Fig 3), a striking difference in survival (P = .013) between these two groups was demonstrated; patients in the highest quartile had a median PFS of only 9 months (CI, 3 to 16 months), versus 28 months (CI, 8 to >99 months) for those in the lowest quartile. Thus, there is both an increase in the number of patients with progressive disease (ie, reduced long-term PFS, Fig 2) and an acceleration of the rate of disease progression (Fig 3), in association with high pretreatment circulating tumor ganglioside levels.

The potential clinical application of these results is demonstrated by the analysis of a group of patients previously assumed to have a uniform prognosis. This group, children

---

**Table 1. Circulating G\textsubscript{D2} Ganglioside Concentration at Diagnosis in Patients With Advanced Stage Neuroblastoma**

<table>
<thead>
<tr>
<th>Clinical Stage</th>
<th>Circulating G\textsubscript{D2} Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median</td>
</tr>
<tr>
<td>III (n = 32)</td>
<td>178*</td>
</tr>
<tr>
<td>IV (n = 42)</td>
<td>295</td>
</tr>
<tr>
<td>III + IV (n = 74)</td>
<td>237</td>
</tr>
</tbody>
</table>

*pmol/mL; stage III versus IV, P > .05.

---

![HPTLC pattern of total circulating gangliosides. G\textsubscript{D2} is indicated by the arrow and the migration of standard gangliosides is marked. Patient samples (lanes 1 through 3) contained 1,200, 650, and 100 pmol G\textsubscript{D2}/mL plasma, respectively. The faint G\textsubscript{D2} band in lane 3 is distinctly visible on the original HPTLC. The gangliosides of normal human plasma are shown in lane 4.](image-url)
Table 2. Outcome of Patients Two Years Postdiagnosis Related
to Pretreatment Circulating GD2 Concentration

<table>
<thead>
<tr>
<th>Quartiles</th>
<th>Range (pmol/mL)</th>
<th>PD</th>
<th>NPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1*</td>
<td>≤50 - 125</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>2</td>
<td>125 - 244</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>3</td>
<td>250 - 590</td>
<td>11</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>704 - 2,160</td>
<td>12</td>
<td>1</td>
</tr>
</tbody>
</table>

Abbreviations: PD, progressive disease; NPD, stable disease.
*All patients surviving 2 years without PD or having had PD within 2 years of diagnosis are included (n = 52); patients with NPD but follow-up of less than 24 months are excluded.
†Patients were grouped into quartiles (n = 13) according to the GD2 concentration: 1, lowest; 4, highest.

with stage IV disease who are older than 1 year at the time of diagnosis, have an almost uniformly fatal outcome (<20% long-term survival).1,15,16 However, the 36 such patients in this study showed marked heterogeneity of circulating GD2 levels at diagnosis. Fifteen of the 36 patients had circulating GD2 levels in the highest quartile. Fourteen of these 15 patients (94%) had PD by 1 year from diagnosis. In contrast, only 11 of 21 patients (53%) with lower GD2 concentrations had PD at this time. Thus, despite otherwise poor prognostic factors (age and stage), GD2 levels below those of the highest quartile (ie, ≤568 pmol/mL) were associated with an almost 50% chance for survival, compared with the much lower survival predicted for this group on the basis of age and stage alone.

DISCUSSION

This study shows the existence of a relationship between circulating tumor-derived ganglioside concentration at diag-

Fig 2. Circulating GD2 concentration at diagnosis and the occurrence of disease progression by 2 years postdiagnosis. Patients are grouped into quartiles (see text and Table 2).

Fig 3. Kaplan-Meier analysis of PFS of neuroblastoma patients. The survival of the quartiles of patients with the lowest (——) and highest (-----) GD2 levels at diagnosis are compared.
Progression has been proposed (in contrast to ferritin,23 neuron-specific enolase,24 and catecholamines25) as the other marker for which a pathogenetic role has been suggested is the N-myc oncogene:26 amplification of the N-myc oncogene is believed to impart a high proliferative capability to the tumor cell.26 These two characteristics may be complementary: a tumor cell phenotype exhibiting both amplification of N-myc and significant ganglioside shedding may result in a tumor that is particularly aggressive. This hypothesis and possible correlations between circulating G_{02} and other biologic markers of neuroblastoma warrant testing.

In conclusion, the present data relate significant shedding, measured as high levels of circulating tumor-derived gangliosides at diagnosis, to acceleration of tumor progression in humans, and suggest the consideration and further study of these molecules as circulating tumor markers of biologic significance.

ACKNOWLEDGMENT

We are grateful to the CCGS Neuroblastoma Reference Laboratory and Dr Robert Seeger for cooperation in this study and for providing certain patient samples; and we thank Shirley Brown for preparation of the manuscript.

REFERENCES

Shed tumor gangliosides and progression of human neuroblastoma

L Valentino, T Moss, E Olson, HJ Wang, R Elashoff and S Ladisch